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Abstract
Background: Patients with Opitz GBBB syndrome present with a variable array of developmental
defects including craniofacial, cardiac, and genital anomalies. Mutations in the X-linked MID1 gene,
which encodes a microtubule-binding protein, have been found in ~50% of Opitz GBBB syndrome
patients consistent with the genetically heterogeneous nature of the disorder. A protein highly
related to MID1, called MID2, has also been described that similarly associates with microtubules.
Results: To identify protein partners of MID1 and MID2 we undertook two separate yeast two-
hybrid screens. Using this system we identified Alpha 4, a regulatory subunit of PP2-type
phosphatases and a key component of the rapamycin-sensitive signaling pathway, as a strong
interactor of both proteins. Analysis of domain-specific deletions has shown that the B-boxes of
both MID1 and MID2 mediate the interaction with Alpha 4, the first demonstration in an RBCC
protein of a specific role for the B-box region. In addition, we show that the MID1/2 coiled-coil
motifs mediate both homo- and hetero-dimerisation, and that dimerisation is a prerequisite for
association of the MID-Alpha 4 complex with microtubules.
Conclusions: Our findings not only implicate Alpha 4 in the pathogenesis of Opitz GBBB
syndrome but also support our earlier hypothesis that MID2 is a modifier of the X-linked
phenotype. Of further note is the observation that Alpha 4 maps to Xq13 within the region showing
linkage to FG (Opitz-Kaveggia) syndrome. Overlap in the clinical features of FG and Opitz GBBB
syndromes warrants investigation of Alpha 4 as a candidate for causing FG syndrome.
Background
Opitz GBBB syndrome (OS; Opitz syndrome) is a geneti-
cally and phenotypically complex disorder defined by
characteristic facial anomalies (hypertelorism and varia-
bly labiopalatine and laryngotracheo-esophageal (LTE)
clefting), structural heart defects, as well as anal and geni-
tal anomalies [1,2]. Recently, we and others identified the
MID1 gene (also called FXY) as the underlying cause of
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the X-linked form of the disease [3–5]. Defects in MID1
have been found in ~50% of OS cases consistent with ev-
idence from genetic linkage and cytogenetic studies that at
least one autosomal form of the disorder, at chromosome
position 22q11.2, also exists [6–8]. The deletion of the
same interval produces the 22q11 deletion syndrome,
which encompasses a group of disorders (eg. DiGeorge
and velocardiofacial syndromes) showing some pheno-
typic overlap with OS [6,9]. Collectively, 22q11 anoma-
lies represent one of the most common genetic causes of
malformations (estimated 1 in 5000 live births) [10]. Al-
though progress has recently been made towards elucidat-
ing the genes contributing to the 22q11 deletion
phenotype [11–14], a specific autosomal OS gene has not
yet been identified.
The MID1 gene encodes the defining member of a new
subclass of the RBCC (RING, B-box, Coiled-Coil) family
of proteins. This subclass is characterised by the combina-
tion of both a fibronectin type III motif and a B30.2-like
(or SPRY) domain positioned C-terminal to the RBCC do-
main [15,16]. As in other members of the RBCC protein
family, MID1 forms multiprotein complexes of between
250 and 450 kDa [17]. The MID1 protein, presumably as
part of these complexes, has been shown to associate with
cytoplasmic microtubules along their length and through-
out the cell cycle using immunofluorescence detection of
endogenous MID1, transient expression of GFP-MID1 fu-
sion proteins, and cellular fractionation [5,18]. Most mu-
tations in MID1 that cause OS are truncating mutations
with many, but not all, directly affecting the C-terminal
half of the protein [5]. Interestingly, all examined MID1
mutations disrupt the normal microtubule-associated dis-
tribution and this has been demonstrated to occur in vivo
with endogenous mutant protein and in transient trans-
fection studies using GFP fusion proteins [5,17,18].
An intriguing aspect of OS is the marked intrafamilial var-
iability seen even among related males with the same X-
linked mutation. This observation may be explained by
the fact that other proteins, such as the highly related
MID2 protein that is expressed in some of the same tissues
and also associates with the microtubule network [15,19],
could at least partially compensate for the loss of MID1
[5]. Such a mechanism has also been proposed for other
microtubule-associated proteins, such as tau [20]. Alter-
natively, variations in the level or action of other factors in
the same molecular pathway (for example, a factor encod-
ed by the 22q11.2 locus and/or another component of the
MID1 macromolecular complex) could contribute to this
variability. Both explanations are consistent with the con-
clusion that OS is caused by loss of function of MID1 [5].
In this paper we report the identification of Alpha 4 as an
interacting partner of both the Opitz syndrome protein,
MID1, and the highly related MID2 protein. Alpha 4 is a
unique and highly conserved regulatory subunit of PP2-
type phosphatases, such as PP2A [21–24], and an integral
component of the rapamycin-sensitive signaling pathway
[25]. Our finding that both MID1 and MID2, either as ho-
mo- or hetero-dimers, are able to tether a key regulator of
intracellular signaling to microtubules has significant im-
plications for our understanding of the pathophysiologi-
cal basis of OS and provides additional support for the
hypothesis that MID2 could act as a modifier of the OS
phenotype. Furthermore, as the Alpha 4 g e n e  m ap s  t o
Xq13 [26], our results identify it as a candidate for other
X-linked disorders such as FG (Opitz-Kaveggia) syndrome
that overlaps clinically with Opitz GBBB syndrome.
Results
Yeast two-hybrid screens identify Alpha 4 as an interacting 
partner of both MID1 and MID2
In order to begin to determine the identity of potential in-
teracting factors and the processes with which MID1 is in-
volved, we performed a yeast two-hybrid assay utilising
the full length MID1 protein (which shares 94.9% identi-
ty, 99.9% similarity with mouse Mid1) as bait in a screen
of a mouse 10.5 dpc (days post-coitum) whole embryo
cDNA library. At 10.5 dpc, expression of Mid1 is seen es-
sentially throughout the embryo although strongest levels
of expression are evident in highly proliferating tissues
such as the developing craniofacial region [27]. The use of
the mouse 10.5 dpc whole embryo library was therefore
chosen to maximise the likelihood of detecting function-
ally relevant interactors.
Approximately 1 ×  106 cDNAs were initially screened us-
ing MID1 as bait. Potential interacting clones were select-
ed based on the activation of the three endogenous
reporter genes (His, lacZ, and Leu). Recovery and sequenc-
ing of the positives from the library screen demonstrated
nine cDNA clones with insert sizes ranging from 1.0 kb to
1.3 kb but representing the same gene. Five additional,
singly represented putative interacting clones were also
identified but do not constitute part of this report. Data-
base searches identified the nine similar clones as encod-
ing Alpha 4, a rapamycin-sensitive regulatory subunit of
protein phosphatases 2A (PP2A) and other PP2-type
phosphatases. By comparison with the published murine
Alpha 4 sequence, all clones were judged as being essen-
tially full-length. Notably, the nine in-frame cDNAs repre-
sented a minimum of seven independent clones as 5'
fusion to the GAL4 activation domain occurred at either
nucleotide +4, +7, +10 or +13 and most clones containing
different length polyadenylated tails. To confirm that this
interaction was not an artefact of the independent GAL4
activation domain and DNA binding domain fusion
events, the full-length cDNAs were interchanged such that
Alpha 4 was fused to the GAL4-DBD and MID1 to GAL4-BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
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AD. Co-transformation of these two constructs into
MaV203 gave similar levels of growth on 3AT (Fig 1A), ie.
a level of activation comparable to the strongest interact-
ing proteins, Fos and Jun (Fig 1A, Control E – colony 10).
Given that MID1 and MID2 share 77% overall amino acid
identity (92% similarity), we wished to investigate wheth-
er MID2 was capable of binding to the same proteins,
such as Alpha 4, or whether this interaction was specific
for MID1. This was investigated using two approaches: a
direct yeast two-hybrid test of the ability of MID2 to bind
Alpha 4, and a full two-hybrid screen of the 10.5 dpc
whole mouse embryo cDNA library this time using MID2
as bait. The direct test demonstrated that MID2 did indeed
interact with Alpha 4. Comparison of the growth of the
MID2/Alpha 4 transformed yeast on plates (SC -Leu, -Trp,
-His) containing 75 mM 3AT indicated the interaction be-
tween MID2 and Alpha 4 was as strong, or stronger, than
that observed for MID1 (Fig 1A). A similar result was ob-
tained when assessing the conversion of Xgal (data not
shown). In the full yeast two-hybrid screen, some poten-
tially novel interactors were identified for MID2. Howev-
er, the majority of the putative interacting clones, and
again the only sequences represented more than once in
the isolates, represented Alpha 4.
MID1 and MID2 tether Alpha 4 to the microtubules
To investigate whether Alpha 4 also associated with MID1
and MID2 in a homologous (mammalian) system, we co-
transfected both GFP-MID1 (or MID2) with myc epitope-
tagged Alpha 4. Transfection of the myc-tagged Alpha 4
expression construct alone resulted in a diffuse distribu-
tion of the myc-Alpha 4 fusion protein throughout the cy-
toplasm in most cells (Fig 1B; g, h). However, in some
cells, a faint filamentous distribution that resembled the
appearance of microtubules could be seen along with the
cytoplasmic protein (data not shown). In contrast, in all
cells co-transfected with GFP-MID1 and myc-tagged Al-
pha 4, there was negligible diffuse cytoplasmic staining.
Instead, essentially all the myc-tagged Alpha 4 protein dis-
played a filamentous meshwork of staining that com-
pletely co-localised with MID1 along the length of the
microtubules (Fig 1B; a-c). This result also suggested that
MID1 was a limiting factor in the tethering of Alpha 4 to
the microtubule network, a conclusion supported by
western analysis that shows low levels of MID1 in these
cells (data not shown). Co-expression of GFP-MID2 and
myc-tagged Alpha 4 similarly resulted in co-localisation
along the microtubules (Fig 1B; d-f).
Alpha 4 does not co-localise with MID1 or MID2 proteins 
harboring in-frame B-box deletions
Both endogenous mutant MID1 protein in OS patient
cells [18] and various transiently expressed mutant MID1-
GFP fusion proteins form cytoplasmic clumps
Figure 1
Alpha 4 interacts with MID1 and MID2. (A) Yeast two-hybrid
analysis of the interaction between MID1 and Alpha 4 as well
as MID2 and Alpha 4. Yeast agar plate (leu- trp- his-, 75 mM
3-AT) showing growth for MID1/Alpha 4 and MID2/Alpha 4
interactions as well as positive control two-hybrid combina-
tions and no growth for negative controls. (B) Detection of
full-length myc tagged-Alpha 4 when co-expressed with GFP-
MID1 and GFP-MID2 fusion proteins in transiently trans-
fected Cos1 cells. (a) GFP-MID1 fluorescence (green), (b)
anti-myc antibody detecting myc-Alpha 4 localisation (red),
(c) overlay of (a), (b) showing co-localisation of the myc-
Alpha 4 fusion protein and GFP-MID1, with DAPI stain for
DNA (blue). (d) GFP-MID2 fluorescence (green), (e) myc-
Alpha 4 localisation (using same detection as b) (red), (f)
overlay of (d), (e) with DAPI (blue) showing co-localisation of
the myc-Alpha 4 fusion protein and GFP-MID2. (g) Detection
of transiently expressed myc-Alpha 4 fusion protein in Cos1
cells, (h) overlay of (g) and DAPI stain showing cytoplasmic
distribution of myc-Alpha 4 fusion protein.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
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[5,15,17,18]. We chose to exploit this previous observa-
tion by co-transfecting GFP-tagged MID1∆ CTD (or
MID2∆ CTD) with a construct expressing a myc-tagged Al-
pha 4 protein in order to investigate whether Alpha 4 still
remained bound to MID1 within such aggregates. The re-
sults clearly showed a distribution of myc-Alpha 4 that
was indistinguishable from the clumped MID1∆ CTD and
MID2∆ CTD truncated proteins, indicating that Alpha 4
indeed aggregates with the truncated MID1 and MID2
proteins (Fig 2B; m-o).
To further define the motif in MID1 (and MID2) respon-
sible for the interaction with Alpha 4, we generated in-
frame deletions of all other motifs (Table 1) and fused the
resulting clones to GFP. We initially transfected each con-
struct alone to examine the effect of each deletion on the
intracellular localisation of the proteins. The results
showed that each motif, or at least their conserved spacing
or arrangement, was essential for the distribution of MID1
(and MID2) along the length of the microtubules. The dis-
tribution of the individual domain deleted MID proteins
when transfected alone was indistinguishable from their
distributions when transfected along with myc-Alpha 4
(see below). Consequently, the GFP fluorescence images
in Fig 2B can also be considered a representation of each
distribution pattern in the absence of co-transfected myc-
Alpha 4. Like the ∆ CTD constructs, deletion of either the
B-boxes or the FNIII domain also resulted in cytoplasmic
clumps or speckles although these usually appeared
smaller and greater in number and the speckles still ap-
peared to co-localise with microtubules (data not shown).
Both ∆ RING proteins, in contrast, showed variability in
their distribution with most transfected cells still showing
association along the length of the microtubules. Howev-
er, the microtubule association of these ∆ RING proteins
often did not extend to the cell periphery. Notably, dele-
tion of the coiled-coil motif in each protein resulted a dif-
fuse cytoplasmic distribution, suggesting that these
proteins had lost their ability to associate with microtu-
bules (see Fig 2B; g-i).
We then individually co-transfected each MID1 (and
MID2) deletion construct with myc-Alpha 4 in an attempt
to define the domain responsible for the interaction with
Alpha 4. Co-transfection of either the ∆ RING or ∆ FNIII
proteins with myc-Alpha 4 (Fig 2B; a-c and j-l, respective-
ly) resulted in co-localisation of Alpha 4 with the abnor-
mally distributed MID1 and MID2 proteins, as seen with
the ∆ CTD proteins. Co-expression of either ∆ CC construct
with Alpha 4 resulted in both proteins exhibiting a diffuse
cytoplasmic distribution although the pattern of each was
still suggestive of the two proteins being able to interact
(Fig 2B; g-i). Strikingly, when either of the ∆ BB constructs
was co-expressed with Alpha 4, the mutant MID1 and
MID2 proteins still formed cytoplasmic clumps but, in
Figure 2
MID1/Alpha 4 and MID2/Alpha 4 interactions are maintained
in all MID domain-specific deletions except for those involv-
ing the B-boxes. (A) Yeast two hybrid analysis shows that the
MID B-boxes are required for interaction with Alpha 4. The
interaction of Alpha 4 with MID1∆ BB (21), or MID2∆ BB (23),
is compared to its interaction with MID1∆ CC (22), or
MID2∆ CC (24). (B) Subcellular localisation of myc tagged-
Alpha 4 when co-expressed in Cos-1 cells with MID1
domain-specific deletions as GFP fusion proteins. Fluores-
cence detection of GFP-MID1∆ RF (a), GFP-MID1∆ BB (d),
GFP-MID1∆ CC (g), GFP-MID1∆ FNIII (j), and GFP-
MID1∆ CTD (m). Anti-myc antibody detection of myc-Alpha
4 in the same cells as expressing the various MID1 domain-
specific deletions (b,e,h,k,n). Overlay of the GFP and anti-myc
images of the same cells merged with DAPI stain of nuclei
(c,f,i,l,o). All merged images, with the exception of (f) show
co-localisation of myc-Alpha 4 with the various MID1 domain
deletions. In (f), myc-Alpha 4 fails to co-localise with GFP-
MID1∆ BB in small cytoplasmic aggregates.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
Page 5 of 14
(page number not for citation purposes)
both cases, Alpha 4 remained diffuse in the cytoplasm (Fig
2B; d-f). These results imply that the B-boxes (and/or the
linker residues between the B-boxes and RING motifs) are
primarily responsible for the interaction with Alpha 4.
To confirm these results, we cloned the MID1 and MID2
domain-deletion constructs in-frame into pPC86 and co-
transformed into MaV203 with pDBLeu-Alpha 4. As ex-
pected from the immunofluorescence data, activation of
all two-hybrid reporter genes, at a level similar to that seen
with the full-length MID proteins, was observed with the
∆ RING, ∆ FNIII and ∆ CTD proteins (results not shown),
confirming that neither of these domains mediated bind-
ing to Alpha 4. Notably, both ∆ CC proteins also interact-
ed with Alpha 4 (Fig 2A) suggesting that the two proteins
were indeed still interacting in the cytoplasm in the im-
munofluorescence experiments despite not being associ-
ated with microtubules. However, the strength of the
interaction between the ∆ CC proteins and Alpha 4 ap-
peared to be reduced compared to the full-length, ∆ RING,
∆ FNIII and ∆ CTD (data not shown). In contrast, but again
confirming the immunofluorescence result, the ∆ BB con-
structs did not activate reporter gene expression indicating
the interaction between Alpha 4 and either MID protein
was abolished by removal of this motif (Fig 2A).
The coiled-coil domains of MID1 & MID2 are required for 
homodimerisation and microtubule binding but not Alpha 
4 interaction
Immunoprecipitation experiments have previously
shown that MID1 can form homodimers/homomultim-
ers [17]. To investigate whether homodimerisation was a
prerequisite for binding Alpha 4 and/or association with
the microtubules, we first tested whether MID1 can inter-
act with itself in the context of the yeast two-hybrid sys-
tem. The results clearly indicated that the MID1-MID1
interaction is strong (Fig 3A). Domain-deletion constructs
(in pDBLeu and pPC86 vectors) were then introduced
into the yeast two-hybrid system. Unlike the proteins har-
boring a deletion of either the RING, B-boxes or FNIII mo-
tifs, the MID1 protein lacking the coiled-coil motif had
significantly reduced capacity to bind the wild-type MID1
protein, inferring that the coiled-coil domain is critical for
efficient homodimerisation (result not shown). Assess-
ment of MID1 using the MultiCoil algorithm [28] sup-
ports the conclusion of dimer formation (not trimer) and
that the first of the two coiled-coils in this domain is large-
ly responsible for this property. Interestingly, the MID1
protein in which the CTD motif was removed also dem-
onstrated a reduced ability to bind the wild-type MID1 in
this system, although this effect was not as marked as that
seen for the ∆ CC proteins. Notably, the yeast two-hybrid
and immunofluorescence experiments demonstrate that
Alpha 4 can still interact with the MID1 and MID2 ∆ CC
proteins. This observation indicates that Alpha 4 must be
able to interact with MID monomers although its tether-
ing to the microtubule network is dependent on MID
dimerisation, that is; the MID proteins only associate with
microtubules as dimers.
MID1 & MID2 can form heterodimers on microtubules
Given their high level of identity, we investigated whether
MID1 and MID2 can also form heterodimers using the
yeast two-hybrid system, immunofluorescence of tran-
siently transfected Cos1 cells and co-immunoprecipita-
tion. Co-transformation of the yeast MaV203 strain with
both pDBLeu-MID1 and pPC86-MID2 (or in the reverse
vector combination) resulted in high level activation of all
reporter genes indicating a strong interaction that was
comparable to the strength of the MID1-MID1 homo-in-
teraction (Fig 3A). These findings are contradictory to ini-
tial reports from a study by Cainarca et al [17] but have
been confirmed in experiments involving transient trans-
fection of GFP-MID1 and myc-MID2 fusion constructs
(Fig 3B) as well as by co-immunoprecipitation (Fig 3C).
Introduction of individual domain-deletions of MID1 to-
gether with full-length or domain-deletion MID2, and
vice versa, into Cos1 cells and the yeast strain MaV203 us-
ing the relevant constructs showed, as expected, that the
coiled-coil motif was largely responsible for mediating
this heterodimerisation (data not shown).
Table 1: The MID1 and MID2 deletion constructs used in pEGFP-
C2 for cellular co-localisation analysis, co-immunoprecipitation 
and in pPC86/pDBLeu for interaction analysis with Alpha 4. 
Terms: RF denotes a C3HC4 RING finger; BB denotes C2H2 B-
Boxes; CC denotes a Coiled-coil motif; FNIII denotes a Fibronec-
tin Type III domain and CTD denotes a C-terminal domain (en-
compassing a SPRY domain).
Construct Amino Acids deleted
Mid1∆ RF 1–69
Mid1∆ BB 71–213
Mid1∆ CC 214–349
Mid1∆ FNIII 370–473
Mid1∆ CTD 483–667
Mid2∆ RF 1–69
Mid2∆ BB 71–213
Mid2∆ CC 214–349
Mid2∆ FNIII 370–473
Mid2∆ CTD 483–686
BB(Mid1) 1–70 and 214–667
CC(Mid1) 1–213 and 350–667
BBCC(Mid1) 1–70 and 350–667BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
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The B-boxes of MID1 & MID2 are sufficient to bind Alpha 
4
To verify that the Alpha 4 interaction and the association
of the complex with microtubules were indeed dependent
on the B-boxes and coiled-coil, respectively, and not just
an artefact of altering the relative spacing of remaining do-
mains, we fused the MID1 B-boxes and coiled-coil motif,
or the coiled-coil motif alone, in-frame to GFP and co-
transfected with the myc-Alpha 4 construct. Of interest
was the observation that the MID1 coiled-coil domain
alone fused to GFP (GFP-M1CC) resulted in cytoplasmic
clumping (Fig 4B; a), supporting the notion that the
coiled-coil domain is required for MID1 dimerisation.
Consistent with this is that the phenomenon of cytoplas-
mic clumping seen in most OS patients has only been ob-
served in those cases where the expressed mutant MID1
protein harbours a mutation outside the coiled coil motif
[5]. Notably, however, in cells co-transfected with the
GFP-M1CC and myc-Alpha 4 constructs, Alpha 4 did not
co-localise with these M1CC clumps (Fig 4B; a-c). Like the
M1CC protein, the construct expressing the fusion be-
tween GFP and the MID1 B-boxes plus coiled-coil do-
mains (GFP-M1BBCC) resulted in clumps within the
cytoplasm. Importantly, and in contrast to the co-transfec-
tion of M1CC, Alpha 4 was found to co-localise with the
GFP-M1BBCC fusion protein (see Fig 4B; d-f). We did not
undertake the generation of a GFP-M1BB (B-boxes alone)
construct as it was predicted that the resultant GFP fusion
protein would show a diffuse cytoplasmic distribution
largely indistinguishable from Alpha 4. Instead, the MID1
B-boxes were cloned into pDBLeu and tested directly for
their ability to interact with Alpha 4 in the two-hybrid sys-
tem. The result (Fig 4A) clearly supports the conclusion
that the B-boxes are sufficient to bind Alpha 4.
Figure 3
MID1 and MID2 can homo- and heterodimerise with one another. (A) Yeast two-hybrid assay for MID1 and MID2 multimeri-
sation. Yeast agar plate (leu- trp- his-, 75 mM 3-AT) showing growth for MID1/MID1 (25), MID1/MID2 (26 and 27) and MID2/
MID2 (28). (B) MID1 and MID2 co-localise to the microtubules. Co-expression of GFP-MID1 (a) and myc-MID2 (b) in tran-
siently transfected Cos1 cells showing co-localisation to the microtubular cytoskeleton in an overlay (c) with a DAPI stained
nucleus (blue). (C) Co-immunoprecipitation of MID1 and MID2 homo- and heterodimers. Shown are extracts from Cos1 cells,
transfected with GFP-MID1 (lane 1), GFP-MID2 (lane 2), myc-MID1 (lane 3), myc-MID2 (lane 4), GFP-MID1 and myc-MID1
(lane 5), GFP-MID2 and myc-MID1 (lane 6), GFP-MID1 and myc-MID2 (lane 7) and GFP-MID2 and myc-MID2 (lane 8). Samples
were immunoprecipitated with anti-GFP antibody/protein-A sepharose beads, separated on a 8% SDS polyacrylamide gel,
transferred to a nitrocellulose membrane and blotted with anti-c-myc antibody to detect co-precipitate protein.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
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Figure 4
The B-boxes of MID1 are sufficient to bind Alpha 4. (A) Yeast two-hybrid analysis shows that the MID1 B-boxes (pPC86-
M1BB) alone can interact with Alpha 4 (pDBLeu-Alpha 4) (31). The wild-type MID1-Alpha 4 interaction (30) and a control with
the pPC86-M1BB and no interaction partner (29) were included for comparison. (B) Immunofluorescence assay highlights the
importance of the B-boxes for Alpha 4 binding. Subcellular distribution of the GFP-fused MID1 coiled coil domain, GFP-M1CC
(a) and myc-Alpha 4 (b) in the same cell shows that the two proteins do not co-localise, as seen in the merged image (c). How-
ever, the MID1 fragment, GFP-M1BBCC (d) and the myc-Alpha 4 (e) do co-localise in cytoplasmic speckles as seen in the
merged image (f). Both merged images, (c) and (f), also show DAPI stain (blue), which indicates the position of the nucleus.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
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MID1 is phosphorylated on serine and threonine residues
As Alpha 4 is a regulator of PP2-type serine/threonine
phosphatases, we investigated whether MID1 and MID2
might themselves be phosphorylated and hence possible
targets of Alpha 4/phosphatase action. Due to the low lev-
els of endogenous MID1 and MID2 in all tested cultured
cell lines, we performed western analysis of immunopre-
cipitated MID-GFP proteins using extracts of Cos1 cells
that had been transiently transfected with the various ex-
pression constructs. Immunoprecipitation with anti-GFP
antibodies followed by western analysis using anti-phos-
phoserine and anti-phosphothreonine antibodies showed
that MID1- and MID2-GFP fusion proteins were phos-
phorylated on both serine and threonine residues (Fig
5A). Similar analysis using anti-phosphotyrosine antibod-
ies failed to demonstrate phosphorylation of tyrosine res-
idues on either protein (result not shown).
In an attempt to define the location of the sites in MID1
that were phosphorylated, we performed similar immu-
noprecipitation and western analysis but this time using
extracts of Cos1 cells that had been transfected with the
individual domain-specific deletion constructs (Fig 5B).
That the overall phosphorylation of the MID1 fusion pro-
tein was not significantly affected by deletion of any indi-
vidual domain may suggest that MID1 is phosphorylated
at multiple threonine residues along the protein. Howev-
er, using the anti-phosphoserine antibody, no serine
phosphorylation of the ∆ BB protein was detected suggest-
ing that most serine phosphorylation in MID1 occurs at or
near the B-boxes.
Identification of potential sites of phosphorylation in 
MID1 and MID2
Computer prediction of potential target residues for phos-
phorylation by serine/threonine kinases not surprisingly
identified numerous consensus sites throughout both hu-
man MID1 and MID2. Given the conservation of the ra-
pamycin-sensitive pathway from yeast to mammals and
the fact that Alpha 4 binds to both MID1 and MID2 which
are only 77% identical, we reasoned that any functionally
relevant phosphorylation site should be conserved across
species and in both MID1 and MID2 proteins. Examina-
tion of available orthologous MID1 and MID2 sequences
(from seven and three species, respectively) showed that
sixteen of these sites (6 threonines and 10 serines) were
fully conserved between all MID proteins (Fig 5C). Inter-
estingly, two of these sites (Ser92 and Ser96), which rep-
resent consensus phosphorylation sites for GSK3 and
MAPK/CKI/CKII respectively, are the only two conserved
serine residues in the amino-terminal half of the protein
and, as both are located in the region deleted in the ∆ BB
constructs of MID1 and MID2, are likely to be the primary
sites of serine phosphorylation in these proteins.
Discussion
We have previously shown that the X-linked form of Opitz
GBBB syndrome (OS) results from loss of function muta-
tions in MID1, a gene that encodes a member of a new
class of microtubule-associated proteins [5]. A highly re-
lated factor, termed MID2, has also been identified which
shares 77% amino acid identity (92% similarity) with
MID1 and is expressed in many of the same embryologi-
cal tissues, albeit at a lower level in most [15,19]. Both
MID1 and MID2 are members of the RBCC family of pro-
teins, a group of proteins with diverse intracellular locali-
sations and presumably varied functions. Despite these
differences, an ability to function as part of large multi-
protein complexes is common to RBCC proteins [29].
Consistent with this is the observation that the 67 kDa
MID1 is mostly found in complexes of between 250 kDa
and 450 kDa [17]. However, no function has been defini-
tively ascribed to any of the motifs in the MID proteins or
indeed either protein as a whole. In this study, we have
undertaken yeast two-hybrid screens to identify interact-
ing partners that were likely to constitute part of these
MID-complexes as well as performed precise deletion
analysis of the MID proteins to begin to elucidate the role
of individual motifs.
The only apparent similarity between all the MID1 muta-
tions identified in patients with OS is that the resultant
mutant protein is no longer able to completely decorate
the microtubules. This observation implies that the func-
tion of one or more proteins within the MID1 complex is
absolutely required along the length of the microtubules.
Identification of such bona fide interactors might therefore
be expected to shed light on the possible role of the OS
protein and thus provide a better understanding of the
molecular pathogenesis of the disorder. To this end, we
performed yeast two-hybrid screens using MID1 and
MID2 as bait and a 10.5 dpc mouse embryo cDNA library
as prey. Significantly, we identified the phosphoprotein,
Alpha 4 (also known as IGBP1) as an interactor of both
MID proteins. This interaction between the MID proteins
and Alpha 4 was confirmed by both vector swapping in
the two-hybrid system as well as by co-localisation of dif-
ferentially tagged proteins to the microtubule network.
The specificity of this interaction is also supported by the
fact that mouse Mid1 (but not mouse Mid2 presumably
because of its lower abundance) was recently identified in
the reverse two-hybrid screen of a 9 dpc murine embryon-
ic cDNA library where the mouse Alpha 4 was used as the
bait [30]. To characterise this interaction further, we chose
to exploit the observation that C-terminal mutations of
MID1 form cytoplasmic clumps both in vivo[18] and in
transformed cell lines over-expressing GFP-mutant MID1
fusion proteins [5,15,17,18] by co-transfecting constructs
expressing the ∆ CTD proteins (and the other domain-spe-
cific deletions of MID1 and MID2) as GFP fusions withBMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
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Figure 5
MID1 contains phosphorylated serine and threonine residues. (A) Extracts from untransfected Cos1 cells (lanes 1 & 3) or Cos1
cells transfected with GFP-MID1 (lanes 2 & 4) were immunoprecipitated with anti-GFP antibody/protein-A sepharose beads
and analysed by western blot analysis using either an anti-phosphoserine antibody (lanes 1 & 2) or anti-phosphothreonine anti-
body (lanes 3 & 4). Protein bands in lanes 2 and 4 indicated that GFP-MID1 contains both phosphoserine and phosphothreo-
nine residues. (B) Domain-specific deletions of MID1 were used in an attempt to crudely map locations of the phosphorylated
serine and threonine residues. Shown are extracts from Cos1 cells transfected with full length GFP-MID1 (lane 1), GFP-
MID1∆ RF (lane 2), GFP-MID1∆ BB (lane 3), GFP-MID1∆ CC (lane 4), GFP-MID1∆ FNIII (lane 5), and GFP-MID1∆ CTD (lane 6).
The samples were immunoprecipitated with anti-GFP antibody/-protein-A sepharose beads, separated on 8% SDS polyacryla-
mide gels, transferred to nitrocellulose membranes and blotted with anti-phosphoserine antibody (top panel) or anti-phospho-
threonine antibody (bottom panel). (C) Computer assisted detection of potential serine/threonine phosphorylation sites in
MID1. Potential serine/threonine kinase consensus phosphorylation sites in MID1 were identified using NetPhos 2.0 software
[38]. Examination of a multiple alignment of available MID1 and MID2 sequences was carried out to identify fully conserved
putative phosphorylation sites. A diagrammatic representation of this analysis shows 16 conserved sites depicted as dots (red
for serine and blue for threonine) along the length of a representative MID1 protein (numbered residue positions are also
depicted at the top of diagram). The actual kinases that recognise the residues are listed on the left of the figure; CaMII (R-X-
X-S/T-X), CKI (Sp/Tp-X2–3-S/T-X), CKII (X-S/T-X-X-D/E), GSK3 (X-S/T-X-X-X-Sp), MAPK (P-X-S/T-P), PKA (R-X1–2-S/T-
X), PKC (X-S/T-X-R/K), PKG ((R/K)2–3-X-S/T-X).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
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the myc-tagged Alpha 4 construct. These experiments were
complemented by yeast two-hybrid analysis of the same
combinations of constructs.
Through a series of in-frame deletions of both MID1 and
MID2 employed in both immunofluorescence and yeast
two-hybrid assays, we have demonstrated functions for
three domains of these RBCC proteins. We have shown a
direct role for an RBCC B-box region in protein-protein
interactions, that being the binding of Alpha 4, a regulato-
ry subunit of the PP2-type phosphatases including the
principal cellular phosphatase, protein phosphatase 2A
(PP2A; [21–24]). In addition to the identified role for the
B-boxes, we have shown that the coiled-coil domain not
only mediates the homodimerisation of these proteins
but also their ability to heterodimerise. Finally, our data,
together with previous observations by others [18], sup-
port a role for the C-terminal domain in microtubule
binding and to a lesser extent in dimerisation. Collective-
ly, the immunofluorescence and yeast two-hybrid data in-
dicate that MID dimerisation is a prerequisite for
association of each MID-Alpha 4 complex with microtu-
bules.
The interaction of MID1 and MID2 with Alpha 4 raised
the possibility that these RBCC proteins, like Xnf7, are
phosphoproteins. Indeed, western blot analysis of the
transiently expressed MID-GFP fusion proteins using anti-
phosphoserine and anti-phosphothreonine antibodies
has confirmed these suspicions. Analysis of the domain-
specific deletion proteins using these same antibodies
showed that most serine phosphorylation of MID1 seems
to occur at, or immediately adjacent to, the B-boxes,
whereas threonine phosphorylation was likely to occur at
residues in more than one domain. As a preliminary step
towards identifying those residues that are phosphorylat-
ed, computer-based searches identified numerous poten-
tial sites for phosphorylation by serine/threonine kinases.
However, only sixteen of these (see Fig 5C) are completely
conserved across all MID species isolated to date. Of note
are the potential phosphorylation sites at serine 96 (S96;
[30]) and serine 92 (S92) that are located immediately
amino-terminal to the B-boxes of MID1 and MID2 and
are deleted in the ∆ BB constructs. S92 is a consensus site
for GSK3 that would be dependent on prior phosphoryla-
tion of S96. S96 falls within a consensus phosphorylation
sequence for the MAP-kinase (MAPK), ERK2 (P-N-S/T-P;
[31]), as well as casein kinases I and II. Therefore, either of
these kinases could conceivably play a priming role for
GSK3 phosphorylation of S92. Similar phosphorylation
mechanisms have been observed for other proteins in-
cluding some microtubule-associated proteins, eg. tau
and MAP2, where it has been implicated in the regulation
of specific functions of those proteins [32,33]. Notably, in
the case of both eIF2Bepsilon (at serine residues 535 &
539) and tau (at serine residues 208 & 212), DYRK, a
MAPK-related kinase, plays such a priming role for GSK3
[34]. However, DYRK is unlikely to be involved in phos-
phorylation of MID1 S96 because of a single amino acid
difference in its surrounding sequence required for recog-
nition of this site for phosphorylation. In fact, Liu et al
[30] have provided evidence to support the involvement
of a MAPK, although the target of this activity was not
shown. Irrespective of the identity of the kinase(s) respon-
sible, it is conceivable that phosphorylation at these or
other sites in MID1 and MID2 could play an important
role in the overall function of the MID proteins, for exam-
ple: regulation of the Alpha 4-MID interaction and hence
regulation of PP2-type phosphatase activity. However, our
preliminary analysis of a MID1 Ser92/Ser96 double mu-
tant has suggested that MID dimerisation and the MID-Al-
pha 4 interaction are not dependent on phosphorylation
at these residues (unpublished observations).
Regardless of the role of MID phosphorylation, the impli-
cation of both MID1 and MID2 in the Alpha 4-mediated
regulation of phosphatase activity may provide valuable
clues as to the pathophysiological consequences of MID1
mutations that underlie Opitz syndrome. It can be envis-
aged that, in tethering Alpha 4 to the microtubules, MID1
(and MID2) could be affecting the activity of the PP2-type
phosphatases and thereby, in-turn, modulating the ra-
pamycin-sensitive signaling pathway. This could conceiv-
ably occur by one of a number of mechanisms. Firstly, the
MID proteins may control the availability of Alpha 4 to
the phosphatases either by its 1) sequestration or 2) turn-
over, facilitated by the possible role of the MID RING fin-
ger motif in ubiquitination. Secondly, the Alpha 4-MID
interaction may direct PP2A (and PP2-related) phos-
phatase activity to specific targets on the microtubules,
which may include MID1 and MID2 themselves. The fact
that both endogenous MID1 and transiently expressed
GFP-MID1 and GFP-MID2 decorate microtubules
throughout the cell cycle ([17]; unpublished observa-
tions) suggests that binding of MID1 and MID2 to the mi-
crotubule network may not itself be regulated by targeted
Alpha 4-dependent PP2A activity. However, it remains
possible that dynamic regulation of MID1 microtubule
binding may escape detection by immunofluorescence as
endogenous levels of MID1 and Alpha 4 in examined cell
lines are both low (unpublished observations). The fact
that we have not been able to demonstrate PP2A(C) co-lo-
calisation with the MID-Alpha 4 complexes on the micro-
tubules, despite a known microtubule-associated pool of
PP2A [35], would perhaps support the former of these
mechanisms. However, we cannot exclude the possibility
that recognition of PP2A(C) by this antibody is blocked
by the interaction of Alpha 4 and MID1/2. If this is indeed
the case, then it could be envisaged that PP2A(C) is also a
target of MID RING-mediated degradation through its in-BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
Page 11 of 14
(page number not for citation purposes)
dependent interaction with Alpha 4. An alternate hypoth-
esis is that MID function is indeed controlled by Alpha 4-
PP2-type phosphatases but through the regulated binding
of additional factors that might be components of the
MID1 macromolecular complexes. The characterisation of
additional interacting partners will therefore be important
to assess this possibility.
Numerous studies in mice have demonstrated that Alpha
4, like its yeast homologue Tap42, plays an essential regu-
latory role within the cell through its regulated binding to
the catalytic (C) subunit of PP2-type serine/threonine
protein phosphatases [21–24]. The interaction of Alpha 4
with PP2A(C) has been most extensively studied and
shown to be dependent on phosphorylation of Alpha 4 by
the mTOR (target of rapamycin) kinase. Although PP2A
has a wide range of biological functions, Alpha 4 regulates
a distinct subset of events in a rapamycin-sensitive man-
ner, including progression through the cell cycle and the
regulation of protein biosynthesis (for a review see [36]).
The implication that disruption to some aspects of this ra-
pamycin-sensitive pathway might be associated with the
pathogenesis of the developmental disorder, Opitz syn-
drome, raises two intriguing possibilities. Firstly, it can be
envisaged that mutations in other components of the
pathway may give rise to similar clinical phenotypes. It is
therefore perhaps worthy to note that the Alpha 4 gene
maps to Xq13 [26] in the vicinity of the critical interval for
FG syndrome, a malformation disorder with some clinical
overlap with that of Opitz GBBB syndrome. We are cur-
rently investigating whether molecular defects in Alpha 4
indeed underlie FG syndrome or other developmental dis-
orders mapping to the proximal long arm of the X chro-
mosome. Secondly, it is also feasible that genetic
polymorphisms that reflect a variation in the level of ex-
pression or activity of one or more components of the ra-
pamycin-sensitive pathway might also contribute to the
clinical variability of OS. In this regard, the indication
from our immunofluorescence studies that the microtu-
bular localisation of Alpha 4 is likely to be limited by the
level of the MID1 and MID2 proteins within a particular
cell type provides indirect support for our earlier hypoth-
esis that MID2 may be able to compensate, at least partial-
ly, for the loss of MID1 in Opitz syndrome [5].
Conclusions
The finding that Alpha 4, a rapamycin-sensitive regulatory
subunit of PP2-type phosphatases, interacts strongly with
the RBCC proteins, MID1 and MID2, implicates this sign-
aling pathway in the pathogenesis of the X-linked form of
Opitz GBBB syndrome and provides a possible explana-
tion for the intrafamilial variability in clinical presenta-
tion of the disorder. Other components of the rapamycin-
sensitive pathway should be considered as candidates for
similar malformation disorders.
Materials & Methods
Miscellaneous enzymes and chemicals
All restriction endonucleases were purchased from New
England Biolabs (Genesearch Pty Ltd, Arundel, Queens-
land), Klenow fragment from GeneWorks Pty Ltd (The-
barton, South Australia), and both T4 ligase and T4 DNA
polymerase from Roche Diagnostics Australia (Castle Hill,
New South Wales). 4',6-diamidine-2-phenylindole' dihy-
drochloride (DAPI) and 3-Amino Triazole (3AT) were ob-
tained from Sigma-Aldrich (Castle Hill, New South
Wales).
The yeast two-hybrid screen
The ProQuest™ yeast two-hybrid system (Invitrogen, Mul-
grave, NSW) was employed to screen for potential inter-
acting partners of MID1. In order to generate the "bait"
construct, the full-length human MID1 cDNA was sub-
cloned from pBSMID1 [5] using SalI and NcoI into the
similarly restricted pDBLeu vector. Subsequent digestion
with SalI, end-filling with Klenow fragment and religation
generated the full-length MID1 cDNA in-frame with the
GAL4 DNA binding domain (Gal4DBD). The construct,
pDBLeu-MID1, was verified by sequencing.
The selection of an appropriate cDNA library was deemed
critical to maximise the chance of detecting bona fide inter-
acting factors. The expression of the murine Mid1 gene
during embryological development is consistent with the
clinical presentation of OS [27]. Given the very high level
of primary sequence identity between all vertebrate MID1
proteins (unpublished data), a murine 10.5 dpc whole
embryo cDNA library (Invitrogen) directionally cloned in
the GAL4 activation domain (GAL4-AD) plasmid, pPC86,
was selected for use as the "prey" in the two-hybrid screen.
The pDBLeu-MID1 construct was transformed into
MaV203 strain (Genotype: MATα , leu2–3, 112, trp1–901,
his3∆ 200,  ade2–101,  gal4∆ ,  gal80∆ ,  SPAL10::URA3,
GAL1::lacZ,  HIS3UAS  GAL1::HIS3@LYS2,  can1R,  cyh2R)
along with the parental pPC86 plasmid as per the manu-
facturers instructions (Invitrogen). The HIS3 reporter was
used to determine the level of self-activation of the MID1-
GAL4DBD fusion based on the level of 3-amino triazole
resistance (3ATR) of the fusion protein. A concentration of
50 mM 3AT was found to be an adequate level for the as-
say, although subsequent analyses were performed on 75
mM 3AT plates to further reduce background transactiva-
tion of the reporter genes. To screen for potential interact-
ing proteins, the pDBLeu-MID1 fusion construct was co-
transformed with the 10.5 dpc mouse embryo cDNA-
pPC86 library according to standard protocols (Pro-
Quest™ Yeast Two-Hybrid Manual, Invitrogen) and plated
on a synthetic complete medium (SC-Leu-Trp-His) con-
taining either 50 mM or 75 mM 3AT.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
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The full-length MID2 (FXY2) cDNA was cloned from
pEGFP-FXY2.ORF [15] into pDBLeu using the same strat-
egy as used for MID1. As Mid2 is generally expressed in
many of the same tissues during embryological develop-
ment as Mid1 albeit at considerably lower levels [19], the
resultant clone, pDBLeu-MID2, was consequently used as
"bait" in a similar screen of the 10.5 dpc embryo cDNA li-
brary as well as directly against the identified MID1 inter-
acting clones.
For confirmation of putative interacting clones, constructs
and library clone isolates (in both parental vectors and
swapped vectors) were re-transformed into the MaV203
yeast strain using the LiAc method [37]. Transformed
yeast cultures were incubated for 24 hours at 30°C in se-
lective media. Cultures (10 µl – 0.1 OD600) were then
spotted onto selective plates and incubated at 30°C for 48
hours. Replica cleaning of plates was performed as re-
quired.
Generation of GFP- and myc-full-length cDNA fusion con-
structs for immunofluorescence
The generation of full-length MID1-GFP and MID2-GFP
fusions in pEGFP have previously been reported [15,5]. A
vector for the production of myc-tagged fusion proteins
was generated by modification of the pEGFP-N2 vector
(Clontech, Palo Alto, CA). Briefly, the GFP coding region
was excised from pEGFP-N2 with NotI and BamHI, the 5'
overhangs filled using T4 DNA polymerase and the vector
religated to give pCMV-N2. Six copies of the myc epitope
containing a start codon was amplified from pGEM-
6mycT (gift from M. Whitelaw, University of Adelaide),
and cloned into the HindIII site of pCMV-N2. To facilitate
in-frame insertion of cDNAs directly from the pPC86 li-
brary vector, the plasmid was linearised with EcoRI, end-
filled and re-ligated to create pCMV-6myc-∆ E. In order to
clone Alpha 4 into pCMV-6myc-∆ E, pPC86-Alpha 4 was
digested with SalI/AatII and the full-length cDNA insert
ligated into SalI/SmaI restricted pCMV-6Myc-∆ E vector.
The reading frame of the construct was confirmed by au-
tomated sequencing.
Generation of MID1 and MID2 domain-specific deletion 
constructs for immunofluorescence and yeast two-hybrid 
analyses
The FNIII domain-specific deletions in both MID1 and
MID2 were generated by precise deletion of the domains
by a two-step PCR strategy. The other domain-specific de-
letion constructs were generated using QuickChange™
site-directed mutagenesis (Stratagene, La Jolla, CA) to in-
troduce unique restriction sites, as required, at the start
and end of each domain within MID1 and MID2. Excep-
tions to this were the RING and B-box deletions of MID1
where a native XbaI site located at nucleotides +207–212
was used as the 3' and 5' excision point in the respective
constructs, and the CTD deletions in both MID1 and
MID2 where a native BamHI site located at nucleotides
+1464–1469 was used as the 5' excision point for these
constructs. Restriction sites were chosen so that, where
possible, the encoded amino acid sequence remained un-
altered or only resulted in conservative substitutions. Fur-
thermore, the sites were positioned such that excision of
individual domains did not alter the reading frame of the
encoded protein (Table 1). In any one construct, a maxi-
mum of two restriction sites were introduced. Details of
the strategies and primers (for both PCR and site-directed
mutagenesis) used in the generation of these deletion
constructs will be forwarded upon request to the corre-
sponding author. Each introduced restriction site was con-
firmed by digestion and sequencing and then
independently tested for its effect on the microtubule
binding capacity of the respective proteins. In each case,
this was determined by direct visualisation of fluorescence
of the created GFP fusion protein. No introduced change
had any appreciable effect on the microtubular distribu-
tion of the proteins.
To further test the function of some of the regions of the
MID1 protein, selected separate motifs were generated us-
ing the appropriate existing, and/or inserted, restriction
sites and ligated in-frame and C-terminal to either EGFP
(in pEGFP) or Gal4DBD (in pDBLeu). The following con-
structs were generated: the MID1 B-box fusion (pDBLeu-
M1BB) containing residues 71–213, the MID1 coiled-coil
fusion (pEGFP-M1CC) containing residues 214–349, and
the MID1 B-boxes plus coiled-coil fusion (pEGFP-
M1BBCC) containing residues 71–349.
Transfection and immunofluorescence analysis of GFP-
MID1 constructs
Preparations of the various GFP- and myc-tagged expres-
sion constructs were made using the Qiagen Midi kit (Qia-
gen, Clifton Hill, Victoria). Two picomoles
(approximately 1 microgram) of each construct were
transfected into cultured cell lines (Cos1, HeLa, NIH3T3)
using FuGene transfection reagent (Roche Diagnostics
Australia). Transfected cells were grown on coverslips in
DMEM plus 10% FBS and fixed 24 hours post-transfection
as previously described [5].
In test transfections, where only a single GFP expression
construct was introduced into cells, control microtubule
staining was performed post-fixation using an anti-α  tu-
bulin antibody plus an anti-mouse Texas Red-conjugated
secondary antibody (Jackson Laboratories, Bar Harbor,
Maine). In cells transfected with myc-tagged expression
constructs (either alone or in combination with a GFP-
tagged expression construct), anti-α  tubulin staining was
not performed. Instead the Texas Red-conjugated second-
ary antibody was used in combination with an anti-mycBMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/1
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monoclonal antibody (9E10) to detect the expression of
the myc-tagged protein. In all cases, nuclei were stained
using the DNA-specific stain, DAPI. GFP and Texas Red
fluorescence were visualised under appropriate wave-
length light on an Olympus AX70 microscope. Images
were captured using a Photometrics CE200A Camera Elec-
tronics Unit and processed using Photoshop 6.01 soft-
ware (Adobe Systems Incorporated, San Jose, California).
Immunoprecipitation and western analysis
Preparations of the various GFP- and myc-tagged expres-
sion constructs were made using a DNA plasmid Midi kit
(Qiagen). Six picomoles (approximately 3 micrograms) of
each construct were transfected into approximately 107
Cos1 cells using FuGene transfection reagent (Roche Di-
agnostics Australia). After 24 hours incubation, cells were
scraped from the culture dish and lysed on ice for 30 min-
utes in 1 ml lysis buffer (50 mM Tris-Hcl pH 7.4, 300 mM
NaCl, 5 mM EDTA, 1.0 % Triton X-100). Cell lysates was
cleared by centrifugation at 4°C (15 minutes, 16 × g), and
protein extract recovered as supernatant. After pre-clearing
200 µl of protein extract with 10 µl of 50% protein-A
sepharose bead slurry, extracts were incubated with 1 µg
of antibody for 2 hours at 4°C and then for another 2
hours with 20 µl of fresh 50% protein-A sepharose bead
slurry. The beads were washed four times with wash buffer
(50 mM Tris-Hcl pH 7.4, 300 mM NaCl, 5 mM EDTA,
0.1% Triton X-100) and protein eluted from the beads by
boiling in 2 ×  SDS load buffer. Proteins were separated by
8% SDS PAGE and blotted onto Hybond-C membranes
(Amersham Pharmacia) using a semi-dry transfer appara-
tus (BioRad). Membranes were blocked, incubated with
the appropriate primary antibody, washed, incubated
with the appropriate HRP-conjugated secondary antibody
and washed again according to established method de-
scribed in Current Protocols in Cell Biology. Detection
was carried out using an enhanced chemiluminescence re-
agents (ECL) kit (Amersham Pharmacia) as per the man-
ufacturer's instructions. Antibodies used in
immunoprecipitation and western blot analysis included;
rabbit polyclonal anti-GFP antibody (gift from Pam Sil-
ver, Dana-Farber Cancer Institute, Boston), mouse anti-c-
myc monoclonal antibody (gift from Stephen Dalton,
University of Adelaide), rabbit polyclonal anti-phospho-
serine and anti-phosphothreonine antibodies (Zymed)
and HRP conjugated anti-rabbit and anti-mouse second-
ary antibodies (Amersham Pharmacia).
Computer-assisted detection of serine/threonine phospho-
rylaton sites
Analysis of putative consensus serine/threonine phospho-
rylation sites in MID1 was performed using NetPhos ver-
sion 2.0  [http://www.cbs.dtu.dk/services/NetPhos/]
software [38]. Examination of a multiple sequence align-
ment of all available MID1 and MID2 sequences was per-
formed in order to determine if any putative
phosphorylation site was fully conserved. For this analy-
sis, orthologous MID1 sequences were assessed from a va-
riety of species, including human, mouse, rat, chick,
tammar wallaby, zebrafish (partial sequence only) and
fugu, and MID2 orthologous sequences from human,
mouse and rat (partial sequence only).
Note Added In Proof
During the review of this manuscript, a paper by Trocken-
bacher et al [Trockenbacher A, Suckow V, Foerster J, Win-
ter J, Krauβ  S, Roper H-H, Schneider R. and Schweiger S:
MID1, mutated in Opitz syndrome, encodes an ubiqui-
tin ligase that targets phosphatase 2A for degradation.
Nature Genetics 2001, 29:287–294] independently report-
ed the interaction of Alpha 4 and MID1. These investiga-
tors also showed that MID1, possibly through Alpha 4,
regulates the turnover of the microtubule-associated frac-
tion of PP2AC and hence may represent a possible patho-
logical mechanism for the Opitz syndrome phenotype.
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